GLK-33

About Glykos Finland

Glykos is a Finnish biotech company specializing in next-generation antibody-drug conjugates (ADCs) for oncology. Its core innovation is a proprietary platform featuring hydrophilic linkers and novel payloads (including auristatin, anthracyclin, and exatecan classes) designed to significantly widen the therapeutic window. The company is in late preclinical development with a lead candidate targeting CD33 for AML and MM, and has secured a major collaboration with Orion Corporation, signaling strong validation of its technology. Glykos operates as a private, preclinical-stage firm combining internal pipeline development with platform licensing and service offerings.

Therapeutic Areas